Arguing against this possibility is the fact that we and others have not found significant differences in pre-chemotherapy Ang-2 levels between different disease groups, even in cancers with significant angiogenic activity, such as multiple myeloma [22,42]. This evidence concerns the gene ANGPT2 and plasma cell myeloma.